Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- CSIMC Approves Plans for FY2013 Market Price Survey of Similar Size as 2 Years Ago
June 14, 2013
- CSIMC Expert Subcommittee: Reps Agree on Need to Redress Price Variations of Generics
June 13, 2013
- Japan’s Target Drug Market Size Revised Up to 12.8 Trillion Yen in 2020: Growth Strategy
June 13, 2013
- Reprocessing of Expired Anti-Influenza Drugs to Be Considered “If Necessary”
June 13, 2013
- Only About 50% of Doctors Aware of ADR Relief System: PMDA
June 12, 2013
- Half of Patients Unaware of New Anticoagulants: Healthy Japan 21 Promotion Forum Survey
June 11, 2013
- Expert Subcommittee to Begin Discussions on Next Year’s NHI Price Revision on June 12
June 11, 2013
- Director Kamada of HPB’s Economic Affairs Division Calls for Cooperation in Promoting Distribution Reform
June 11, 2013
- Bill to Amend PAL Unlikely to Be Enacted in Current Diet Session
June 10, 2013
- MHLW to Establish “PMDA-WEST” in Kansai Region in October
June 10, 2013
- Council Announces “Comprehensive STI Strategy” to Create One Trillion Yen Market for Regenerative Medicine by 2030
June 10, 2013
- Japan Set to Perk Up R&D to Expand Drug Market to 9 Trillion Yen in 2020
June 7, 2013
- MHLW Asks Industry Organization to Take Steps to Ensure Proper COI Management in Response to Diovan Scandal: HPB Director-General at Diet
June 7, 2013
- Abe Vows to Lift Ban on Online OTC Drug Sales; MHLW to Form Panel to Verify Safety
June 6, 2013
- Novartis Pharma Taking Steps to “Clean Up Its Act” in Wake of Diovan Scandal: Minister of Health Tamura
June 5, 2013
- Study Group Fails to Reach Agreement on Online Sales of OTC Drugs; Final Report to Collate Different Views
June 4, 2013
- Provisional Measure Allowing Online Sales of Class 2 and 3 OTC Drugs to Be Extended to End of 2013: MHLW
June 4, 2013
- MHLW to Look into Correlations of Pediatric Drug Intakes and Adverse Reactions
June 3, 2013
- 14 APIs/26 Products Including Third Domestic Biosimilar Receive Listing
June 3, 2013
- FDA Approves World’s First MEK Inhibitor Discovered by JT
May 31, 2013
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…